SELLAS Receives IMPD Approval from the French Regulatory Authority for its Pivotal Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment